Rakovina Therapeutics Inc. (TSXV:RKV)

Canada flag Canada · Delayed Price · Currency is CAD
0.1450
-0.0050 (-3.33%)
Feb 27, 2026, 3:29 PM EST
Market Cap3.07M -88.5%
Revenue (ttm)n/a
Net Income-8.28M
EPS-0.55
Shares Out21.15M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,506
Average Volume28,878
Open0.1500
Previous Close0.1500
Day's Range0.1450 - 0.1500
52-Week Range0.0850 - 1.6000
Beta-0.52
RSI48.42
Earnings DateApr 28, 2026

About Rakovina Therapeutics

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Varia... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Kim Oishi
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol RKV
Full Company Profile

Financial Performance

Financial Statements